Gilead Sciences (GILD) | Stock Overview & Key Data
Gilead Sciences Performance Comparison
Stock Range
Today's Range
Low: $114.18
High: $117.63
on September 12, 2025
52 Week Range
Low: $81.57
High: $121.83
on September 13, 2024
All-Time High: $123.37 on June 22, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$142.1B
EPS
5.04
P/E Ratio (TTM)
22.73
Forward P/E
15.42
P/B Ratio
7.23
PEG Ratio
1.05
Div. Yield
3.25%
ROE
33.40%
Beta
0.379
Debt to Equity
127.34
Financial Highlights
Profitability
Gross Margin
78.80%
Operating Margin
39.16%
Profit Margin
21.87%
Returns and Earnings
Return on Assets (TTM)
12.62%
Return on Equity (TTM)
33.40%
EBITDA
$13.9B
Net Income (TTM)
$6.3B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$23.16
Quarterly Revenue Growth (YoY)
1.80%
Quarterly Earnings Growth (YoY)
21.40%
Dividend Information
Last 12-Month Dividend
$3.91
Current Dividend Yield
3.25%
3-Year Average Dividend Yield
0.91%
3-Year Average Annual Dividend
$3.30
3-Year Total Dividends
$9.91
Ex-Dividend Date
September 15, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences GILD | 142.13B Large-cap | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% | 38.33% | 74.62% | 76.10% |
| Eli Lilly and LLY | 691.79B Mega-cap | 3.88% | 18.13% | -6.98% | -8.09% | -2.91% | -18.22% | 144.55% | 389.97% |
| Johnson & Johnson JNJ | 428.83B Mega-cap | -0.21% | 3.06% | 13.66% | 9.34% | 23.64% | 7.58% | 6.24% | 19.36% |
| Amgen AMGN | 148.80B Large-cap | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% | -16.83% | 19.62% | 11.61% |
| Pfizer PFE | 137.10B Large-cap | -4.06% | -3.16% | -3.90% | -7.16% | -10.30% | -18.45% | -48.14% | -31.31% |
| Bristol-Myers Squibb BMY | 94.04B Large-cap | -1.99% | -0.75% | -8.86% | -22.76% | -18.65% | -5.94% | -35.39% | -22.03% |
Ownership & Short Interest
Insider Ownership
0.10%
Institutional Ownership
90.75%
Shares Short
18M
Short Ratio
2.79
Short % of Shares Outstanding
1.42%
Average 10-Day Volume
7M
Average 90-Day Volume
6M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GILD's 52-week high and low?
- In the last 52 weeks, Gilead Sciences reached a high of $121.83 (on N/A) and a low of $81.57 (on September 13, 2024).
- What is the market cap and P/E ratio for GILD?
- Curious about Gilead Sciences's size and valuation? Its market capitalization stands at 142.13B. When it comes to valuation, the P/E ratio (trailing twelve months) is 22.73, and the forward P/E (looking ahead) is 15.42.
- Does GILD pay dividends? If so, what's the yield?
- Yes, Gilead Sciences is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.25%, and the company has paid an average of $3.30 per share annually over the past 3 years.
- Who are Gilead Sciences's main competitors or similar companies to consider before investing?
When looking at Gilead Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY691.79B Healthcare Drug Manufacturers - General -18.22% 144.55% Johnson & Johnson
JNJ428.83B Healthcare Drug Manufacturers - General 7.58% 6.24% Amgen
AMGN148.80B Healthcare Drug Manufacturers - General -16.83% 19.62% Pfizer
PFE137.10B Healthcare Drug Manufacturers - General -18.45% -48.14% Bristol-Myers Squibb
BMY94.04B Healthcare Drug Manufacturers - General -5.94% -35.39% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Gilead Sciences, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Gilead Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 33.40%, the Debt to Equity ratio from the most recent quarter is 127.34, and its Gross Profit Margin stands at 78.80%.
- What is the recent revenue and earnings growth for GILD?
- Looking at Gilead Sciences's growth, its revenue over the trailing twelve months (TTM) was $29B. Compared to the same quarter last year (YoY), quarterly revenue grew by 1.80%, and quarterly earnings saw a YoY growth of 21.40%.
- How much of GILD stock is held by insiders and institutions?
- Wondering who owns Gilead Sciences stock? Company insiders (like executives and directors) hold about 0.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 90.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.